Intermediate Dose of Intravenous Melphalan in Advanced Multiple Myeloma | Citedby Results | Oncology | Karger Publishers

Skip to Main Content

Skip Nav Destination

Intermediate Dose of Intravenous Melphalan in Advanced Multiple Myeloma

Oncology (1991) 48 (5): 369–371.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

A. Romano
A. Chiarenza
U. Consoli
C. Conticello
S. Forte
G. Uccello
C. Vetro
M. Cavalli
F. Coppolino
G.A. Palumbo
F. Di Raimondo

Annals of Oncology (2013) 24 (4): 1038.

A Phase I–II trial of polyethylene glycol‐conjugated L‐asparaginase in patients with multiple myeloma

Neeraj R. Agrawal
Ronald M. Bukowski
Lisa A. Rybicki
Joanne Kurtzberg
Lewis J. Cohen
Mohamad A. Hussein

Cancer (2003) 98 (1): 94.

The use of intravenous intermediate dose melphalan and dexamethasone as induction treatment in the management of de novo multiple myeloma

S. A. Schey
M. Kazmi
R. Ireland
A. Lakhani

European Journal of Haematology (1998) 61 (5): 306.

Cyclophosphamide and etoposide therapy with GM‐CSF for VAD‐resistant multiple myeloma

Meletios A. Dimopoulos
Kay B. Delasalle
Richard Champlin
Raymond Alexanian

British Journal of Haematology (1993) 83 (2): 240.